Blog

The Global Burden of Disease Study 2019 estimates that 52.5 million people worldwide have epilepsy [1]. The primary goal in the treatment of epilepsy is the elimination of seizures, typically achieved using anti-seizure medications (ASM). However, a substantial treatment gap exists in the United States, with upwards of 30% of individuals newly diagnosed with epilepsy remaining untreated with any ASMs at three years [2]. Effective treatment of epilepsy as a public health concern requires closing this gap by extending the utilization of ASMs in those with new diagnoses of epilepsy.